|
|
|
21.08.25 - 13:03
|
I-Mab to Participate in September Investor Conferences (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md., Aug. 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the following upcoming investor conferences in September, 2025:...
|
|
|
|
|
|
|
01.08.25 - 15:01
|
Everest Medicines Expands Strategic Investment in I-MAB (PR Newswire)
|
|
|
- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive......
|
|
|
|
|
01.08.25 - 14:03
|
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the pricing of an underwritten offering in the United States of 33,333,334 American Depositary Shares (ADSs) representing 76,666,668 ordinary shares at an offering price of $1.95 per ADS, for total gross proceeds of approximately $65 million. All of the ADSs to be sold in the offering will be offered by I-Mab. The offering is expected to close on August 5, 2025, subject to customary closing conditions....
|
|
|
|
|
17.07.25 - 13:03
|
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md., July 17, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that it entered into a definitive agreement to acquire 100% ownership of Bridge Health Biotech Co., Ltd. (Bridge Health). The transaction provides I-Mab with the rights to bispecific and multi-specific applications (including bispecific and multi-specific antibodies and antibody drug conjugates (ADCs)), based on the Claudin 18.2 (CLDN18.2) parental antibody used in the Company's CLDN18.2 x 4-1BB bispecific antibody, givastomig....
|
|
|
14.07.25 - 13:03
|
I-Mab to Present at the BTIG Virtual Biotechnology Conference (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md., July 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 2025....
|
|
|
|
|
|
|
|
|
|
|
|
|
12.06.25 - 13:03
|
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md., June 12, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that on June 11, 2025 it received notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Listing Rule”). The Company's American Depositary Shares (“ADSs”) will continue to be listed and traded on Nasdaq....
|
|
|
|
|
|
|
03.06.25 - 13:03
|
I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md., June 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the H.C. Wainwright “HCW@Home” Series, being held virtually on Tuesday, June 17, 2025....
|
|
|
20.05.25 - 13:03
|
I-Mab to Present at Jefferies Global Healthcare Conference (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in the Jefferies Global Healthcare Conference, being held June 3-5, 2025. During the event, I-Mab's management will discuss clinical progress on its lead program, givastomig....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
